This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Disease models			
Mouse models of cancer containing a genetically engineered <i>K-Ras</i> (<i>KRAS</i>) mutation	<p>Genetically engineered mouse models could help predict responses to cancer therapeutics. In mouse models of non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma containing an engineered <i>Kras</i> mutation, a chemotherapeutic alone or in combination with an angiogenesis inhibitor produced results that were similar to those seen in clinical trials using the same compounds. Next steps include using the findings to develop new mouse models of cancer.</p> <p>SciBX 3(22); doi:10.1038/scibx.2010.684 Published online June 3, 2010</p>	Patent application filed; available for licensing	<p>Singh, M. <i>et al. Nat. Biotechnol.</i>; published online May 23, 2010; doi:10.1038/nbt.1640</p> <p>Contact: Leisa Johnson, Genentech Inc., South San Francisco, Calif. e-mail: leisaj@gene.com</p> <p>Contact: Mallika Singh, same affiliation as above e-mail: msingh@gene.com</p>